Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE
description
Transcript of Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE
![Page 1: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/1.jpg)
![Page 2: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/2.jpg)
Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare
DANIELE REGGE
INSTITUTE FOR CANCER RESEARCH AND TREATMENTCANDIOLO-TORINO, ITALY
![Page 3: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/3.jpg)
Rationale of cancer therapy
Since most cancer treatments, especially chemotherapies, have safety risks, a necessary condition that must be satisfied for a patient to accept treatment is that improvement in terms of relevant and reliable clinical benefits will outweigh the harm done by the treatment.
![Page 4: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/4.jpg)
Rationale of cancer therapy
• Direct measures of how a patient feels, is able to function, or whether he or she survives following treatment are considered the only definite and meaningful endpoints of clinical benefit.
• Therefore, it would be logical to expect that most of the evidence provided by clinical research would be based on measures of definite clinical benefit important to the patients, expressed in terms of gains in survival and in the quality of life.
![Page 5: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/5.jpg)
Surrogate end-points
• To detect a clinically meaningful and statistically significant difference in OS the required sample sizes, length of follow-up, and associated costs are often considered to be unaffordable.
• Surrogate endpoints are indirect measures of definite or true clinical benefit.
• Also called intermediate endpoints, surrogate markers, or biomarkers, comprise laboratory, imaging, and physical measurements considered as suitable substitutes for a clinically meaningful endpoints.
![Page 6: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/6.jpg)
Surrogate end-points
• The validation of surrogate endpoints has received increasing attention due to the harm caused by treatments whose efficacy was assessed using non-validated surrogate endpoints.
Grimes DA, Schulz KF (2005) Surrogate end points in clinical research: hazardous to yourhealth. Obstet Gynecol 105:1114-1118
![Page 7: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/7.jpg)
Surrogate end-points
Surrogate Endpoints of Clinical Benefit Giovannino Cicconeand Ileana Baldi, From Imaging Tumor Response to Therapy, Springer 2012
![Page 8: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/8.jpg)
Surrogate end-points
Grimes DA, Schulz KF (2005) Surrogate end points in clinical research: hazardous to yourhealth. Obstet Gynecol 105:1114-1118
![Page 9: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/9.jpg)
Surrogate end-points
Surrogate Endpoints of Clinical Benefit Giovannino Cicconeand Ileana Baldi, From Imaging Tumor Response to Therapy, Springer 2012
![Page 10: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/10.jpg)
Surrogate end-pointsThe above-described experience highlights the critical dilemma surrounding the role of surrogate endpoints in clinical research: on the one hand, they have the potential to make new therapies more rapidly available to patients, but on the other they carry the risk of disseminating useless or harmful treatments, with negative consequences for patients and contributing to the waste of scarce resources.
Surrogate Endpoints of Clinical Benefit Giovannino Ciccone and Ileana Baldi, From Imaging Tumor Response to Therapy, Springer 2012
![Page 11: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/11.jpg)
IMAGING• The aim of using imaging as a surrogate biomarker for
the response to treatment in oncology is threefold:– To obtain a measure of disease extent as a function of
treatment that is more objective and reproducible than achieved by considering symptoms or clinical status.
– To better understand tumour at an earlier time than is possible with other biomarkers or with primary end-points, such as overall survival/mortality or disease-specific survival/mortality.
– To reduce, as the combined consequence of points 1 and 2, either the time or the sample size in clinical trials testing new therapies, including drugs, surgery, or imaging-guided interventional procedures.
Surrogate Endpoints of Clinical Benefit Giovannino Cicconeand Ileana Baldi, From Imaging Tumor Response to Therapy, Springer 2012
![Page 12: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/12.jpg)
IMAGING: WHO criteria (1979-1981)• [(Cross-productFollow-up – Cross-productBaseline)/Cross-
productBaseline] x 100
• In case of multiple lesions in an individual patient, cross-products were summed.
![Page 13: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/13.jpg)
RECIST 1.0 (year 2000)
• Response Evaluation Criteria for Solid Tumors• From 2D to 1D (step backward?)• Use of CT or MRI• Sum of multiple measurements (maximum of 10
target lesions/5 per organ)• Minimum size for target lesions (10mm for spiral
CT; 20mm for non spiral CT and MRI)• Non target lesions were considered as non
measurable lesions
![Page 14: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/14.jpg)
RECIST 1.0 (year 2000)Type of tumour response Category
In case of disappearance of all target and non-target lesions. Complete response (CR)
In case of a ≥ 30% decrease in the longest diameter (instead of the ≥ 50% of the WHO criteria for the cross-product) and/or persistence of non-target lesions.
Partial response (PR)
In case of a ≥ 20% increase in the longest diameter of the target lesions (instead of the ≥ 25% of the WHO criteria for the cross-product), the appearance of one or more new lesions, or unequivocalprogression of already existing non-target lesions.
Progressive disease (PD)
When the case cannot be categorized as CR, PR, or PD. The CR and PR categories needed to be confirmed after at least 28 days.
Stable disease (SD)
![Page 15: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/15.jpg)
2D >>> 1D, a step backward?
1st reader 3cmx4cm = 12cm2 2nd reader 3,45cmx4,6=15,87cm3
WHO = 15,87cm2-12,0cm2/12,0cm2=0,32 i.e. PD (≥ 25%)
T1 T2
![Page 16: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/16.jpg)
2D >>> 1D, a step backward?
1st reader 3cmx4cm = 12cm2 2nd reader 3,45cmx4,6=15,87cm3
RECIST = 4,6cm-4cm/4cm=0,15 i.e. SD (cutoff for PD ≥ 20%)
T1 T2
![Page 17: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/17.jpg)
Higher cutoff for PD in RECIST 1.0
Assuming a spherical tumor volume: a 25% increase in the 2D cross-product is equal to a 40% increase in the 3D volume a 20% 1D increase in the longest diameter is equal to a 44% 2D increase in the cross-product and to a 73% increase in 3D volume
![Page 18: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/18.jpg)
Technological bias
Hampers reliable longitudinal comparisons in clinical trials.
![Page 19: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/19.jpg)
![Page 20: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/20.jpg)
![Page 21: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/21.jpg)
www.recist.com
www.recist.com
![Page 22: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/22.jpg)
![Page 23: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/23.jpg)
![Page 24: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/24.jpg)
![Page 25: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/25.jpg)
![Page 26: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/26.jpg)
![Page 27: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/27.jpg)
![Page 28: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/28.jpg)
![Page 29: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/29.jpg)
![Page 30: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/30.jpg)
![Page 31: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/31.jpg)
![Page 32: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/32.jpg)
![Page 33: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/33.jpg)
![Page 34: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/34.jpg)
Two major limitations of RECIST
• Inter-observer variability• Different morphological behaviour of lesions
when using targeted therapies.
![Page 35: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/35.jpg)
![Page 36: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/36.jpg)
Oxnard G, JCO Vol 29; 2011
![Page 37: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/37.jpg)
Oxnard G, JCO Vol 29; 2011
![Page 38: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/38.jpg)
![Page 39: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/39.jpg)
![Page 40: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/40.jpg)
![Page 41: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/41.jpg)
Specialized software
![Page 42: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/42.jpg)
Lesion Segmentation
![Page 43: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/43.jpg)
123.6 mm3
Pre
92.4 mm3
PostPost
Pre
Lesion Segmentation
![Page 44: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/44.jpg)
![Page 45: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/45.jpg)
![Page 46: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/46.jpg)
Patient report
![Page 47: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/47.jpg)
![Page 48: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/48.jpg)
![Page 49: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/49.jpg)
49
Liver Analysis
Courtesy of Philips
![Page 50: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/50.jpg)
Courtesy of Philips
Liver Analysis
![Page 51: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/51.jpg)
Courtesy of Philips
Resection planning
![Page 52: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/52.jpg)
Two major limitations of RECIST
• Inter-observer variability• Different morphological behaviour of lesions
when using targeted therapies.
![Page 53: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/53.jpg)
![Page 54: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/54.jpg)
Clinical case n° 1
• 71 year old woman• Left radical nefrectomy (Fuhrmam type
I/IV, pT3, lung and pancreatic mets)• August 13th 2007 baseline CT scan
![Page 55: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/55.jpg)
![Page 56: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/56.jpg)
Clinical case n° 2
• 71 year old woman• Left radical nefrectomy (Fuhrmam type
I/IV, pT3, lung and pancreatic mets)• August 13th 2007 baseline CT scan• Three cycles of sunitinib (50mg/day)• Follow-up CT scan 28th of January 2008
![Page 57: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/57.jpg)
SD or PR?
![Page 58: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/58.jpg)
SLD=110mm SLD=93mm
Overall size reduction=15% (SD)
![Page 59: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/59.jpg)
Clinical case n° 2
• 7.11.2011 >>> left radical nephrectomy (Fuhrman 2, pT1b-N1, Mo)
• 22.12.2011 >>> baseline CT scan• 10.1.2012 >>> sunitinib 50 mg/day
(IMA901-301)• 28.3.2012 follow-up CT scan
![Page 60: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/60.jpg)
22.12.2011 28.3.2012
![Page 61: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/61.jpg)
22.12.2011 28.3.2012
![Page 62: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/62.jpg)
22.12.2011 28.3.2012
![Page 63: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/63.jpg)
CHOI Criteria
![Page 64: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/64.jpg)
12 cm 11 cm
93 UH 23 UH
< of lesion density > 15%
![Page 65: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/65.jpg)
CHOI Criteria
![Page 66: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/66.jpg)
CHOI Criteria: results
![Page 67: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/67.jpg)
CHOI criteria (sorafenib 800
mg/die)
Hittinger M, Urologic Oncology: Seminars and Original Investigations 30 (2012) 695–703
![Page 68: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/68.jpg)
CHOI Criteria• Although Choi criteria had a significantly better
predictive value for PFS and OS than RECIST at first evaluation in patients with PR, its predictive value for outcome was similar to that of RECIST at later time points.
• Because Choi criteria were not able to early identify patients with PD, these criteria will not change the management of sunitinib treated mRCC patients.
Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Haanen JB, Boven E (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102:803–809.
![Page 69: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/69.jpg)
Criteria to evaluate response to treatment
![Page 70: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/70.jpg)
104 UH45 UH
10,5 cm
8,3 cm
![Page 71: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/71.jpg)
![Page 72: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/72.jpg)
Criteria to evaluate response to treatment
![Page 73: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/73.jpg)
![Page 74: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/74.jpg)
![Page 75: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/75.jpg)
JUNE 2011 DECEMBER 2011
![Page 76: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/76.jpg)
MASS vs RECIST (84 mRCC)
![Page 77: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/77.jpg)
Lesion volumetry
![Page 78: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/78.jpg)
Lesion volumetry
![Page 79: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/79.jpg)
AJR:194, January 2010
![Page 80: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/80.jpg)
FUNCTIONAL IMAGING/QUANTITATIVE IMAGING
• DCE-US• PERFUSION CT• DCE-MRI• PET/CT
![Page 81: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/81.jpg)
![Page 82: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/82.jpg)
![Page 83: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/83.jpg)
![Page 84: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/84.jpg)
Axel Leon, Radiology. 1980Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis
Radiology 2004
![Page 85: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/85.jpg)
Mappa della permeabilitàMappa della permeabilità
Mappa flusso sanguignoMappa flusso sanguigno Mappa tempo medio di transitoMappa tempo medio di transitoMappa volume sanguignoMappa volume sanguigno
Perfusion CT: renal mass
![Page 86: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/86.jpg)
Fournier LS, Radiology: Volume 256: Number 2—August 2010
![Page 87: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/87.jpg)
Fournier LS, Radiology: Volume 256: Number 2—August 2010
![Page 88: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/88.jpg)
Courtesy of Toshiba
4D perfusion CT
![Page 89: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/89.jpg)
DCE-US
![Page 90: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/90.jpg)
Williams R, Radiology: Volume 260: Number 2—August 2011
![Page 91: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/91.jpg)
DCE-US
![Page 92: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/92.jpg)
DCE-MRI
Decreased enhancement and T1 shortening of tumors on MRI may be useful biomarkers of RCC response to angiogenesis inhibitors.Response criteria combining early changes in size and enhancementlead to better correlation with clinical outcome compared with sizedecrease alone.
![Page 93: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/93.jpg)
PERCIST: PET Response Criteria in Solid Tumor
![Page 94: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/94.jpg)
![Page 95: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/95.jpg)
PET/CT
• A negative PET/CT scan does not exclude the presence of RCC, on the other hand a positive scan is fairly conclusive.
• When mRCC is not FDG-avid then there is no role for FDG-PET.
![Page 96: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/96.jpg)
FDG-PET
![Page 97: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/97.jpg)
![Page 98: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/98.jpg)
![Page 99: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/99.jpg)
![Page 100: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/100.jpg)
![Page 101: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/101.jpg)
Conclusions• RECIST is still now the only criteria to evaluate tumor response
to treatment in the mRCC model, that has been extensively assessed.
• New specialized software will make measurements more reproducible (i.e. lesion segmentation), work-flow faster and yield more comprehensible reports.
• New criteria should include density measurements, but this needs to be validated on larger series.
• Functional Imaging is the future, but we still need to find reliable quantitative indexes, work on standardization of imaging protocols and quality assurance
![Page 102: Interpretazione dell’imaging radiologico dopo terapie a bersaglio molecolare DANIELE REGGE](https://reader031.fdocuments.in/reader031/viewer/2022013101/56814001550346895dab36cf/html5/thumbnails/102.jpg)